Could Crenessity move beyond 21-hydroxylase CAH after Neurocrine’s ENDO 2026 data?
Find out how Neurocrine’s Crenessity data could expand rare CAH treatment thinking while key clinical questions remain.
Pharma & Biotech
Pharma & Biotech
Soleno Therapeutics VYKAT XR data strengthens long-term case in Prader-Willi syndrome
Find out how Soleno Therapeutics’ VYKAT XR data could reshape hyperphagia treatment in Prader-Willi syndrome.
Pharma & Biotech
Neurocrine builds long-term case for Crenessity in congenital adrenal hyperplasia
See how Neurocrine’s two-year Crenessity data may reshape long-term classic CAH care, steroid reduction and pediatric outcomes.
Pharma & Biotech
Neurocrine’s $2.9bn Soleno deal raises the stakes in Prader-Willi syndrome treatment
Find out how Neurocrine’s $2.9bn Soleno acquisition could reshape VYKAT XR’s rare disease launch strategy.
Pharma & Biotech
Neurocrine Biosciences strengthens INGREZZA case with functional improvement data
Mild TD can still disrupt work and independence. Neurocrine’s INGREZZA data raises pressure to rethink when treatment begins.
Pharma & Biotech
Neurocrine’s CAHtalyst pediatric data sharpens the case for CRENESSITY durability
Steroid reduction is the real test in pediatric CAH. Neurocrine’s CRENESSITY data now faces the durability, access and adoption question.